

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



January 5, 2026

Company name	Shin Nippon Biomedical Laboratories, Ltd.
Representative	Representative Chairman, President & CEO Ryoichi Nagata
Listing	TSE PRIME : ticker code 2395
Inquiries	Honorary Executive Director, Head of IR & Corporate Communications, Toshiyuki Iwata
TEL	+81 3 5565 6216

### [Update on Disclosed Matter]

#### **Status of US Subsidiary Satsuma Pharmaceutical's Negotiation for Atzumi™**

As disclosed in the "Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP)" on November 7, 2025, Satsuma Pharmaceuticals, Inc. (hereinafter, "Satsuma"), a consolidated subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, "the Company") in the United States, has been engaged in discussions concerning a potential partnering arrangement for Atzumi™, an intranasal migraine drug. These discussions remain ongoing.

The Company's full-year forecast for consolidated financial results for the fiscal year ending March 31, 2026, announced on May 8, 2025, does not reflect any revenue attributable to Satsuma, while costs are assumed only for the first six months of Satsuma's fiscal year (January to June 2025). In light of the continuing discussions concerning Atzumi™, it is anticipated that Satsuma's second-half costs will be additionally recognized in the fiscal year ending March 31, 2026. The Company is currently undertaking a review of its full-year forecasts and will promptly disclose the anticipated impact of Satsuma on consolidated financial results once a more detailed outlook becomes available.

END